the synthesis of decorated 1,2,3-triazoles via Cu/Pd-catalyzed
click reaction, direct arylation sequence.11 Lauten et al. have
described interesting results on fused 1,2,3-triazole through
cycloaddition followed by direct arylations.12 Cai et al.
trapped CꢀCu formed in CuAAC for intramolecular
Ullmann coupling to synthesize novel fused-1,2,3-
triazoles.13 However, the combination of copper-catalyzed
CuAAC, Ullmann-type coupling and CꢀH functionaliza-
tion is rare in the literature.
Scheme 1. Tandem Reaction of 1a, 2a, and 3 in the Presence of
Copper Catalyst
There are several drugs that contain imidazo[1,2-a]-
pyridine as the core structure such as zolpidem and
alpidem (used for the treatment of anxiety and insomnia),
zolimidine (used for peptic ulcers), and saripidem and
necopidem (for sedative and anxiolytic effects). The deri-
vatives of imidazo[1,2-a]pyridine have shown impressive
biological activities such as antiinflammatory, antibacter-
ial, antiviral, antiulcer, anti-HIV, and immunomodulatory
effects.14 On the basis of the significance of imidazo[1,2-a]-
pyridine nucleus, we believe that further functionalization
leading to fused novel heterocycles will have new and
interesting properties. As a part of our continuous efforts
for the synthesis of novel heterocycles containing imidazo-
[1,2-a]pyridines,15 herein we wish to report a ligand-free
inexpensive copper-catalyzed tandem CuAAC, Ullmann
type CꢀN coupling, and intramolecular direct arylation
for the regioselective synthesis of novel 1,2,3-triazole-fused
imidazo[1,2-a]pyridines.
failed to furnish tandem product, and starting materials
were recovered (entry 3), whereas an inseparable mix-
ture of compounds was observed in the absence of base
(entry 4).
To improve the yield of desired pentacyclic product 5a,
various copper salts, bases, and solvents were screened
(Table 1). Use of CuI and CuO resulted in poor yields,
Cu(OAc)2 gave relatively better yield of desired product
(entries 5, 6, and 7). At the same time CuBr2, Cu(OTf)2,
and Cu2O gave moderate yields of desired product 5a
(entries 9, 10, and 11), whereas CuSO4 resulted in forma-
tion of 4a (entry 8). Among all the screened catalysts,
3-Bromo-2-(2-bromophenyl)imidazo[1,2-a]pyridine (1a),
phenylacetylene (2a) and sodium azide (3) were chosen as
model substrates for the initial investigation, and the results
are summarized in Table 1. In a typical experiment, com-
pound 1a (1 mmol) was treated with 2a (1.2 mmol) and 3
CuCl2 2H2O was found to give the best yield of 5a. Next,
we screened various bases such as KOtBu, Cs2CO3,
K2CO3, Na2CO3, and NaOAc (entries 12ꢀ15) with
3
CuCl2 2H2O as the catalyst. Among these, K2CO3 turned
3
out to be the most effective base to give 5a (entry 2),
whereas use of NaOAc resulted in formation of 4a
(entry 15). Finally, the effect of solvents was also in-
vestigated for this tandem process yielding 5a. Aprotic
polar solvents such as DMF and DMSO were found
to be effective (entries 2 and 16) for this conversion.
1,4-Dioxane and toluene (entries 17 and 18) did not give
any reaction. Use of acetonitrile resulted in formation of
4a (entry 19). Moreover, use of external ligands like N,
N0-dimethylethylenediamine, 1,10-phenonthroline and
L-proline (40 mol %) failed to improve the yield of 5a
(entries 20, 21 and 22).
Having optimized the reaction conditions (Table 1,
entry 2), we investigated the scope of this tandem reaction,
and the results are summarized in Scheme 2. Various
substituted phenylacetylenes smoothly reacted under the
optimized conditions to give desired 1,2,3-triazole-fused
imidazo[1,2-a]pyridines(5aꢀo) inmoderatetogoodyields.
For example, phenylacetylenes with electron-donating
substituents such as 4-methoxy, 4-butyl, 4-pentyl, 4-tert-
butyl, and 3-methyl produced the corresponding 1,2,3-
triazole-fused imidazo[1,2-a]pyridines (5bꢀe and 5n) in
good yields (59ꢀ68%), and 4-fluorophenylacetylene with
electron-withdrawing fluoro group underwent smooth
conversion to afford 62% of 1,2,3-triazole-fused imidazo-
[1,2-a]pyridines (5f). Aliphatic alkynes also efficiently par-
ticipated in tandem reaction to give the corresponding
(1.2 mmol) in the presence of CuCl2 2H2O (20 mol %) and
3
K2CO3 (2.5 mmol) in DMF at 80 °C for 24 h. 3-Bromo-
2-(2-(4-phenyl-1H-1,2,3-triazol-1-yl)phenyl)imidazo[1,2-a]-
pyridine (4a) (Table 1, entry 1) was obtained in 66% yield
(Scheme 1). It was realized that direct Cu-catalyzed arylation
product of 4a can be achieved in one pot at higher tempera-
ture; thus, the reaction temperature was increased to 150 °C
with other conditions keeping similar to entry 1. To our
delight, target compound (5a) was obtained in 65% yield
(entry 2). In the absence of copper catalyst, reaction
(11) (a) Ackermann, L.; Potukuchi, H. K.; Landsberg, D.; Vicente,
R. Org. Lett. 2008, 10, 3081. (b) Ackermann, L.; Potukuchi, H. K. Org.
Biomol. Chem. 2010, 8, 4503.
(12) (a) Panteleev, J.; Geyer, K.; Aguilar-Aguilar, A.; Wang, L.;
Lautens, M. Org. Lett. 2010, 12, 5092. (b) Schulman, J. M.; Friedman,
A. A.; Panteleev, J.; Lautens, M. Chem. Commun. 2012, 48, 55.
(13) Cai, Q.; Yan, J.; Ding, K. Org. Lett. 2012, 14, 3332.
(14) (a) Rival, Y.; Grassy, G.; Taudou, A.; Ecalle, R. Eur. J. Med.
Chem. 1991, 26, 13. (b) Hamdouchi, C.; de Blas, J.; del Prado, M.;
Gruber, J.; Heinz, B. A.; Vance, L. J. Med. Chem. 1998, 42, 50. (c)
ꢁ
ꢀ
ꢀ
Hranjec, M.; Kralj, M.; Piantanida, I.; Sedic, M.; Suman, L.; Pavelic, K.;
Zamola, G. K. J. Med. Chem. 2007, 50, 5696. (d) Lhassani, M.;
Chavignon, O.; Chezal, J. M.; Teulade, J. C.; Chapat, J.-P.; Snoeck,
R.; Andrei, G.; Balzarini, J.; De Clercq, E.; Gueiffier, A. Eur. J. Med.
Chem. 1999, 34, 271. (e) Fisher, M. H.; Lusi, A. J. Med. Chem. 1972, 15,
982. (f) Almirante, L.; Polo, L.; Mugnaini, A.; Provinciali, E.; Rugarli,
P.; Biancotti, A.; Gamba, A.; Murmann, W. J. Med. Chem. 1965, 8, 305.
(g) Couty, F.; Evano, G. In Comprehensive Heterocyclic Chemistry III;
Katritzky, A. R., Ramsden, C. A., Scriven, E. F.V., Taylor, R. J. K., Eds.;
Elsevier: Oxford, 2008; p 409.
(15) Pericherla, K.; Khedar, P.; Khungar, B.; Kumar, A. Chem.
Commun. 2013, 49, 2924.
B
Org. Lett., Vol. XX, No. XX, XXXX